Clinical Trials Logo

Clinical Trial Summary

This is an open-labeled, single-center, Phase I study to evaluate the safety, tolerability, and efficacy of adding apatinib (also known as rivoceranib) to ongoing nivolumab treatment in patients with unresectable or metastatic cancer. Approximately 9-18 subjects in Phase I dose escalation phase and up to 12 additional subjects in Part II expansion phase. Total study duration will be approximately 12 months: 6 months of recruitment plus 6 months of treatment.


Clinical Trial Description

Primary objectives:

- To evaluate the safety and tolerability of apatinib with nivolumab in patients with unresectable or metastatic cancer

- To assess efficacy by objective response rate (ORR), best overall response (BOR), time to response (TTR), and duration of response (DoR) per RECIST v1.1 and iRECIST

- To assess disease control rate (DCR), and duration of disease control (DDC) by RECIST v1.1, and iRECIST

Secondary objectives:

• To evaluate the efficacy of apatinib with nivolumab in patients with unresectable or metastatic cancer as measured by:

- Overall survival (OS)

- Progression-free survival (PFS)

- Event-free survival (EFS)

Exploratory objectives:

- Tumor mutational burden and mutations at baseline and at the time of progression

- Changes in serum cytokines pursuant to treatment response

- Changes in PBMC subsets and MDSC populations as determined by flow cytometry ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03396211
Study type Interventional
Source LSK BioPartners Inc.
Contact Scott Houston
Phone 8013037440
Email scotthouston@lskbiopharma.com
Status Recruiting
Phase Phase 1
Start date December 22, 2017
Completion date December 22, 2019

See also
  Status Clinical Trial Phase
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Active, not recruiting NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Completed NCT01077414 - Phenomenological Study of Psycho-Socio-Spiritual Healing in the Context of Chronic or Life-Threatening Illness
Completed NCT01340846 - A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors Phase 1
Recruiting NCT02565004 - Clinical and Laboratory Analysis of Familial Cancer
Active, not recruiting NCT02502396 - Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center N/A
Recruiting NCT03684005 - MyPatientPal: An App to Help Patients Manage Their Cancer Care N/A
Not yet recruiting NCT03662061 - Assessment of a Multidisciplinary Team Meeting (RCP) in Geriatric Oncology
Recruiting NCT03247309 - TCR-engineered T Cells in Solid Tumors With Emphasis on NSCLC and HNSCC (ACTengine) Phase 1
Completed NCT03272880 - Utilizing the Arts to Improve Health, Resilience, and Well-Being Among Cancer Patients and Their Caregivers N/A
Active, not recruiting NCT00587886 - Estrogen, Diet, Genetics and Endometrial Cancer N/A
Active, not recruiting NCT03548077 - POWERPLAY: Promoting Men's Health at Work N/A
Completed NCT03503838 - A Pilot Study of Online Yoga for MPN Patients N/A
Completed NCT00984035 - Investigation of Cisplatin-Related Kidney Toxicity
Completed NCT01447186 - Adaptation of the American Cancer Society (ACS) Early Detection of Prostate Cancer Patient Decision Aid for Spanish Speaking Men N/A
Recruiting NCT03463941 - Peer Support Dyads in Churches N/A